This is a preview of subscription content, log in via an institution to check access.
References
Pearson TC, Messinezy M . The diagnostic criteria of polycythaemia rubra vera. Leuk Lymphoma 1996; 22 (Suppl 1): 87–93.
Pierre R, Imbert M, Thiele J, Vardiman JW, Brunning RD, Flandrin G . Polycythaemia vera. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours; Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 32–34.
James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in Polycythemia Vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387–397.
Pearson TC, Messinezy M, Westwood N, Green AR, Bench AJ, Huntly BJ et al. A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment. Hematology (Am Soc Hematol Educ Prog) 2000, 51–68.
Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.
Acknowledgements
This work was supported by Grants from la Fondation Pour La Recherche Médicale and La Ligue Nationale Contre le Cancer (équipe labellisée 2004). WV is supported by an interface contract between INSERM and IGR. We are grateful to Drs Aitkaci, Alterescu, Arnaud, Belluci, Benabed, Bengaoua, Brière, Carde, Castaigne, Cheze, Damaj, Darnige, De Revel, Dervite, Desablens, Dupriez, Fouillard, Garidi, Ghomari, Hermine, Kiladjian, Johnson, Letellier, Lemonnier, Livartowski, Macro, Marfaing, Morel, Peltier, Roussy, Seraatrice, Servais, Taksin, Tribout, Varet, Vilque, Wechsler, and Zittoun for their help in collecting samples and clinical data. We are also grateful to the patients for their agreement to participate to this study.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
James, C., Delhommeau, F., Marzac, C. et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 20, 350–353 (2006). https://doi.org/10.1038/sj.leu.2404069
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404069
- Springer Nature Limited
This article is cited by
-
Microrheological disorders in patients with polycythemia vera suffered acute ischemic stroke
Molecular and Cellular Biochemistry (2022)
-
Extrahepatic Portal Venous System Thrombosis in Recurrent Acute and Chronic Alcoholic Pancreatitis Is Caused by Local Inflammation and Not Thrombophilia
American Journal of Gastroenterology (2012)
-
The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis
Journal of Thrombosis and Thrombolysis (2012)
-
Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera
Medical Oncology (2011)
-
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications
Leukemia (2010)